Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1345 to 1350 of 1350 entries
Sorted by: Best Match Show Resources per page
Symptom Burden and Palliative Care Needs of Patients with Incurable Cancer at Diagnosis and During the Disease Course.

The oncologist

Vogt J, Beyer F, Sistermanns J, Kuon J, Kahl C, Alt-Epping B, Stevens S, Ahlborn M, George C, Heider A, Tienken M, Loquai C, Stahlhut K, Ruellan A, Kubin T, Dietz A, Oechsle K, Mehnert-Theuerkauf A, van Oorschot B, Thomas M, Ortmann O, Engel C, Lordick F.
PMID: 33687742
Oncologist. 2021 Jun;26(6):e1058-e1065. doi: 10.1002/onco.13751. Epub 2021 Mar 30.

BACKGROUND: Although current guidelines advocate early integration of palliative care, symptom burden and palliative care needs of patients at diagnosis of incurable cancer and along the disease trajectory are understudied.MATERIAL AND METHODS: We assessed distress, symptom burden, quality of...

Cite
Vogt J, Beyer F, Sistermanns J, et al. Symptom Burden and Palliative Care Needs of Patients with Incurable Cancer at Diagnosis and During the Disease Course. Oncologist. 2021;26(6):e1058-e1065doi: 10.1002/onco.13751.
Vogt, J., Beyer, F., Sistermanns, J., Kuon, J., Kahl, C., Alt-Epping, B., Stevens, S., Ahlborn, M., George, C., Heider, A., Tienken, M., Loquai, C., Stahlhut, K., Ruellan, A., Kubin, T., Dietz, A., Oechsle, K., Mehnert-Theuerkauf, A., van Oorschot, B., Thomas, M., Ortmann, O., Engel, C., Lordick, F. (2021). Symptom Burden and Palliative Care Needs of Patients with Incurable Cancer at Diagnosis and During the Disease Course. The oncologist, 26(6), e1058-e1065. https://doi.org/10.1002/onco.13751
Vogt, Jeannette, et al. "Symptom Burden and Palliative Care Needs of Patients with Incurable Cancer at Diagnosis and During the Disease Course." The oncologist vol. 26,6 (2021): e1058-e1065. doi: https://doi.org/10.1002/onco.13751
Vogt J, Beyer F, Sistermanns J, Kuon J, Kahl C, Alt-Epping B, Stevens S, Ahlborn M, George C, Heider A, Tienken M, Loquai C, Stahlhut K, Ruellan A, Kubin T, Dietz A, Oechsle K, Mehnert-Theuerkauf A, van Oorschot B, Thomas M, Ortmann O, Engel C, Lordick F. Symptom Burden and Palliative Care Needs of Patients with Incurable Cancer at Diagnosis and During the Disease Course. Oncologist. 2021 Jun;26(6):e1058-e1065. doi: 10.1002/onco.13751. Epub 2021 Mar 30. PMID: 33687742; PMCID: PMC8176980.
Copy Download .nbib Format: NLM
Emerging micro- and nanotechnologies in cancer diagnosis and therapy.

Biomedical microdevices

Zhang JXJ, Khademhosseini A.
PMID: 23813078
Biomed Microdevices. 2013 Aug;15(4):579-581. doi: 10.1007/s10544-013-9785-5.

No abstract available.

Cite
Zhang JXJ, Khademhosseini A. Emerging micro- and nanotechnologies in cancer diagnosis and therapy. Biomed Microdevices. 2013;15(4):579-581doi: 10.1007/s10544-013-9785-5.
Zhang, J. X. J., & Khademhosseini, A. (2013). Emerging micro- and nanotechnologies in cancer diagnosis and therapy. Biomedical microdevices, 15(4), 579-581. https://doi.org/10.1007/s10544-013-9785-5
Zhang, John X J, and Khademhosseini, Ali. "Emerging micro- and nanotechnologies in cancer diagnosis and therapy." Biomedical microdevices vol. 15,4 (2013): 579-581. doi: https://doi.org/10.1007/s10544-013-9785-5
Zhang JXJ, Khademhosseini A. Emerging micro- and nanotechnologies in cancer diagnosis and therapy. Biomed Microdevices. 2013 Aug;15(4):579-581. doi: 10.1007/s10544-013-9785-5. PMID: 23813078.
Copy Download .nbib Format: NLM
Evidence in oncology. The Janeway lecture 2000.

Cancer journal (Sudbury, Mass.)

Cox JD.
PMID: 11131481
Cancer J. 2000 Nov-Dec;6(6):351-7.

PURPOSE: The purpose of this address is to evaluate the types of evidence that have fashioned clinical decision making in oncology over the past century and to determine the appropriate weighting of evidence at the start of a new...

Cite
Cox JD. Evidence in oncology. The Janeway lecture 2000. Cancer J. 2000;6(6):351-7
Cox, J. D. (2000). Evidence in oncology. The Janeway lecture 2000. Cancer journal (Sudbury, Mass.), 6(6), 351-7.
Cox, J D. "Evidence in oncology. The Janeway lecture 2000." Cancer journal (Sudbury, Mass.) vol. 6,6 (2000): 351-7.
Cox JD. Evidence in oncology. The Janeway lecture 2000. Cancer J. 2000 Nov-Dec;6(6):351-7. PMID: 11131481.
Copy Download .nbib Format: NLM
Current Practices for Screening and Addressing Financial Hardship within the NCI Community Oncology Research Program.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

McLouth LE, Nightingale CL, Dressler EV, Snavely AC, Hudson MF, Unger JM, Kazak AE, Lee SJC, Edward J, Carlos R, Kamen CS, Neuman HB, Weaver KE.
PMID: 33355237
Cancer Epidemiol Biomarkers Prev. 2021 Apr;30(4):669-675. doi: 10.1158/1055-9965.EPI-20-1157. Epub 2020 Dec 21.

BACKGROUND: Cancer-related financial hardship is associated with poor care outcomes and reduced quality of life for patients and families. Scalable intervention development to address financial hardship requires knowledge of current screening practices and services within community cancer care.METHODS: The...

Cite
McLouth LE, Nightingale CL, Dressler EV, et al. Current Practices for Screening and Addressing Financial Hardship within the NCI Community Oncology Research Program. Cancer Epidemiol Biomarkers Prev. 2020;30(4):669-675doi: 10.1158/1055-9965.EPI-20-1157.
McLouth, L. E., Nightingale, C. L., Dressler, E. V., Snavely, A. C., Hudson, M. F., Unger, J. M., Kazak, A. E., Lee, S. J. C., Edward, J., Carlos, R., Kamen, C. S., Neuman, H. B., & Weaver, K. E. (2021). Current Practices for Screening and Addressing Financial Hardship within the NCI Community Oncology Research Program. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(4), 669-675. https://doi.org/10.1158/1055-9965.EPI-20-1157
McLouth, Laurie E, et al. "Current Practices for Screening and Addressing Financial Hardship within the NCI Community Oncology Research Program." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,4 (2021): 669-675. doi: https://doi.org/10.1158/1055-9965.EPI-20-1157
McLouth LE, Nightingale CL, Dressler EV, Snavely AC, Hudson MF, Unger JM, Kazak AE, Lee SJC, Edward J, Carlos R, Kamen CS, Neuman HB, Weaver KE. Current Practices for Screening and Addressing Financial Hardship within the NCI Community Oncology Research Program. Cancer Epidemiol Biomarkers Prev. 2021 Apr;30(4):669-675. doi: 10.1158/1055-9965.EPI-20-1157. Epub 2020 Dec 21. PMID: 33355237; PMCID: PMC8026561.
Copy Download .nbib Format: NLM
[Cancer diagnosis in general practice is like looking for a needle in a haystack].

Ugeskrift for laeger

Bjerrum L.
PMID: 22409890
Ugeskr Laeger. 2012 Mar 12;174(11):709.

No abstract available.

Cite
Bjerrum L. Kræftdiagnostisk i almen praksis er som at lede efter en nål i en høstak. [Cancer diagnosis in general practice is like looking for a needle in a haystack]. Ugeskr Laeger. 2012;174(11):709
Bjerrum, L. (2012). Kræftdiagnostisk i almen praksis er som at lede efter en nål i en høstak. [Cancer diagnosis in general practice is like looking for a needle in a haystack]. Ugeskrift for laeger, 174(11), 709.
Bjerrum, Lars. "Kræftdiagnostisk i almen praksis er som at lede efter en nål i en høstak." [Cancer diagnosis in general practice is like looking for a needle in a haystack]. Ugeskrift for laeger vol. 174,11 (2012): 709.
Bjerrum L. Kræftdiagnostisk i almen praksis er som at lede efter en nål i en høstak. [Cancer diagnosis in general practice is like looking for a needle in a haystack]. Ugeskr Laeger. 2012 Mar 12;174(11):709. Danish. PMID: 22409890.
Copy Download .nbib Format: NLM
[Circulating tumour DNA in the treatment of cancer].

Ugeskrift for laeger

Iden CR, Johansen AFB, Øgaard N, Kongsfelt IB, Egebjerg K, Andersen CL, Mau-Sørensen M.
PMID: 34378526
Ugeskr Laeger. 2021 Aug 09;183(32).

Circulating tumour DNA analysis has a potential to improve multiple aspects of cancer management. This includes: a) early cancer detection in asymptomatic individuals, b) identification of patients with residual disease after curative intended treatment, c) patient stratification in relation...

Cite
Iden CR, Johansen AFB, Øgaard N, et al. [Circulating tumour DNA in the treatment of cancer]. Ugeskr Laeger. 2021;183(32)
Iden, C. R., Johansen, A. F. B., Øgaard, N., Kongsfelt, I. B., Egebjerg, K., Andersen, C. L., & Mau-Sørensen, M. (2021). [Circulating tumour DNA in the treatment of cancer]. Ugeskrift for laeger, 183(32), .
Iden, Cecilie Riis, et al. "[Circulating tumour DNA in the treatment of cancer]." Ugeskrift for laeger vol. 183,32 (2021).
Iden CR, Johansen AFB, Øgaard N, Kongsfelt IB, Egebjerg K, Andersen CL, Mau-Sørensen M. [Circulating tumour DNA in the treatment of cancer]. Ugeskr Laeger. 2021 Aug 09;183(32). Danish. PMID: 34378526.
Copy Download .nbib Format: NLM
Showing 1345 to 1350 of 1350 entries